argenx SE

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 11 mei 2016 - 07:24

Statutaire naam argenx SE

Titel argenx Reports First Quarter 2016 Financial Results and Provides Business Update

Bericht Breda, the Netherlands / Ghent, Belgium, 11 May 2016 - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced financial results for the first quarter ended 31 March 2016.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201605110000000010_argenx Reports First Quarter 2016 Financial Results and Provides Business Update.pdf (opens in a new window)

Datum laatste update: 22 december 2025